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OBJECTIVES: To provide a functional and phenotypic characterization of immune cells infiltrating small intestinal mucosa during
non-IPEX autoimmune enteropathy (AIE), as to gain insights on the pathogenesis of this clinical condition.
METHODS: Duodenal biopsies from a patient with AIE at baseline and following drug-induced remission were analyzed by
immunohistochemistry, immunofluorescence, and flow cytometry, and results were compared with those obtained from patients
with active celiac disease, ileal Crohn’s disease and healthy controls. Lamina propria (LP) and intraepithelial (IELs) lymphocytes
from AIE and controls were analyzed for mechanisms regulating cytokine production. Foxp3 expression and suppressive
functions of LP regulatory T cells (Tregs) were analyzed.
RESULTS: The quantitative deficit of Foxp3 expression in Tregs in AIE associates with unrestrained IL-17 production by IELs.
Interleukin (IL)-17-producing IELs were rare in the uninflamed duodenum and in the ileum of Crohn’s disease patients, and
disappeared upon drug-induced AIE remission. IL-17 upregulation in CD4+IELs and CD4+LP T cells had different requirements for
pro-inflammatory cytokines. Moreover, transforming growth factor-β (TGF-β) selectively enhanced IL-17 production by CD8+IELs.
Intriguingly, although Foxp3lowTregs in AIE were poorly suppressive, they could upregulate GARP-LAP/TGF-β surface expression
and enhanced IL-17 production selectively by CD8+IELs. Finally, phosphorylated Smad2/3 was detectable in duodenal CD8+
lymphocytes in active AIE in situ, indicating that they received signals from the TGF-β receptor in vivo.
CONCLUSIONS: AIE is characterized by the appearance of unconventional IL-17-producing IELs, which could be generated locally
by pro-inflammatory cytokines and TGF-β. These results suggest that Foxp3+Tregs and Treg-derived TGF-β regulate IL-17
production by IELs in the small intestine and in AIE.
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INTRODUCTION
Autoimmune enteropathy (AIE) is a rare syndrome character-
ized by chronic diarrhea, malabsorption, and severe villous
atrophy, generally associated with autoimmune comorbidities
and circulating anti-enterocyte antibodies.1,2 Most cases of
AIE occur in the context of an X-linked genetic syndrome
known as IPEX (immunodysregulation polyendocrinopathy
enteropathy X-linked syndrome), a disease affecting male
infants, and secondary to mutations in the coding region or in
regulatory elements of Foxp3 gene.3,4 Foxp3, also known as
scurfin, is a forkhead transcription factor essential for the
development and function of CD4+CD25+ regulatory T cells
(Tregs), a subset of T lymphocytes that play a fundamental role
in the regulation of T-cell activation and immune homeostasis.5
Consistently, IPEX patients display a profound defect in Tregs
and a severe reduction of FoxP3 expression in most tissues.6
Nonetheless, in the last few years, non-IPEX adult-onset
forms of AIE are being increasingly reported in both genders.7
These patients exhibit reduced expression of Foxp3 and
reduced suppressive function of CD4+CD25+ Tregs,8 raising
the possibility that defective autosomal genes could also lead
to a deficit of Foxp3 expression and function. These findings
have led to postulate that an unrestricted activation of gut-
associated lymphoid tissue, due to an impairment in Tregs
quantity and/or function, may be responsible for the intestinal
inflammation and villous atrophy which dominate the patho-
logical picture of the syndrome.1 Indeed, immunohistochem-
istry studies have documented a dense mixed T-cell infiltrate
(CD4+ and CD8+) in the duodenal mucosa of patients with
active AIE, which could be associated with a prominent
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intraepithelial lymphocytosis in a significant proportion of
cases.9 This is consistent with the long-known role of activated
T cells and T-cell-derived cytokines in the pathogenesis of
enteropathy and villous atrophy in humans,10 and substanti-
ates the clinical success of T-cell-directed therapies in both
IPEX and non-IPEX AIEs. Indeed, even if clinical manifesta-
tions of AIE usually respond to corticosteroids, steroid-
refractory cases are common, requiring rescue therapy with
additional immunomodulators, such as azathioprine, cyclos-
porine, and tacrolimus, while bonemarrow transplantation has
been employed with some success in severe, drug-refractory
cases.2 Despite these interventions, AIE is still affected by a
high rate of complications and mortality, and novel therapeutic
approaches to control the syndrome are urgently needed. In
order to discover novel targets for selective and more effective
drugs, it is thus highly relevant to obtain insights into character-
istics of infiltrating intestinal inflammatory cells during active
AIE. In this context, existing knowledge regarding AIE path-
ophysiology mostly derive from studies conducted on periph-
eral blood cells or histological sections,6,9,11 while very little is
known regarding phenotypic and functional characteristics of
inflammatory cells that infiltrate the intestinal mucosa.
Here, we report for the first time a detailed phenotypic
and functional analysis of intraepithelial (IELs) and lamina
propria (LP) T lymphocytes that infiltrate the small intestinal
mucosa in a severe case of non-IPEX adult-onset AIE,
following their variations during drug-induced disease remis-
sion. The appearance of unconventional IELs that co-
produced IFN-γ and IL-17 was observed in the duodenal
mucosa, which was largely absent in healthy controls and
patients with celiac or Crohn’s disease, and which relieved
upon pharmacological treatment. This was associated with a
failure of LP CD4+CD25low Treg cells to control IL-17 induction
in IELs. Intriguingly, activated Foxp3lowTregs in AIE upregu-
lated membrane-bound transforming growth factor-β (TGF-β),
and TGF-β strongly enhanced IL-17 induction in CD8+IELs.
These results shed new light on the role of Foxp3+Tregs and
TGF-β in the regulation of intestinal homeostasis in vivo.
METHODS
AIE patient. A 26-year old woman was referred for a
6-month story of severe chronic watery diarrhea, hypokale-
mia, hypoalbuminemia, and severe malnutrition (body
mass index 13.5). Additional findings included thrombocyto-
penia (60.000 platelets/mmc) and low-grade proteinuria.
Upper endoscopy demonstrated scalloping of the duodenal
mucosa. Celiac disease (CD) was ruled out on the basis of
negative serological testing (anti-endomysial and anti-
transglutaminase antibodies), normal immunoglobulin A
levels, and negative genetic testing for HLA-DQ2 and DQ8.
An elevated titer of anti-enterocyte IgG antibodies measured
by indirect immunofluorescence confirmed the diagnosis of
AIE. IPEX syndrome was excluded by the absence of
mutations in the coding and/or in the poly-A region of Foxp3
gene by DNA sequencing (not shown). High-dose steroid
treatment (prednisone 1 mg/kg) was initiated with progressive
clinical and biochemical improvement. Ten weeks after
initiation of steroid treatment, azathioprine therapy (2 mg/kg)
was initiated to maintain disease remission, and steroid
therapy was gradually weaned over 3 months until cessation.
Follow-up endoscopies with duodenal biopsies were per-
formed before treatments (active AIE, PRE), 8 weeks after
initiation of steroid therapy, during clinical remission (T=1),
and at 6 months, during azathioprine treatment (T=2).
Control biopsies. Duodenal biopsies from six age-matched
consecutive patients presenting for gastroesophageal
reflux-related symptoms were used as uninflamed controls.
Standard histological examination of the duodenal mucosa
ruled out organic diseases of the small intestine in all cases.
In addition, ileal biopsies from five patients with endoscopi-
cally and histologically active Crohn’s disease not receiving
steroids, immunosuppressants and/or anti-TNF therapy, were
analyzed as inflamed controls. Crohn’s disease was diag-
nosed on the basis of a combination of clinical, laboratory,
histologic, and radiologic findings.12 Duodenal biopsies from
10 patients with untreated active CD were used as additional
controls. The histopathological diagnosis of CD was based
on typical mucosal lesions with crypt hyperplasia and villous
atrophy. All active CD patients were positive for anti-
endomysial and anti-transglutaminase antibodies at the time
of diagnosis. All patients gave their informed content to the
study, which was performed in accordance with Helsinki
declaration.
Immunohistochemistry and Immunofluorescence. Immu-
nohistochemistry for CD3 (clone 2GV6), CD4 (clone SP35),
and CD8 (SP57), was performed using an automated
staining system (BenchMark ULTRA, Ventana, Roche,
Tucson, AZ). Heat-induced antigen retrieval was automati-
cally obtained using a 0.05 mol/l EDTA solution, pH 8.0 at
95 °C for 30 min. Reactions were revealed using ultraView
Universal DAB Detection Kit (Ventana) in accordance with the
manufacturer's instructions.
For immunofluorescence, paraffin sections from AIE biop-
sies (PRE and POST) and uninflamed duodenal biopsies as
control were submitted to deparaffinization in xylene and
hydration through a series of decreasing alcohol concentra-
tions. Heat-induced antigen retrieval was obtained using Diva
Decloaker solution (Biocare Medical, Concord, CA) at 120 °C
for 3 min in the Decloaker chamber. After blocking and
permeabilization with PBS-BSA 1%-NP40 1% for 30 min,
tissues were incubated with rabbit polyclonal anti-CD8 anti-
body (1:100 ab4055, Abcam, Cambridge, UK) and goat
polyclonal anti-phosphorylated SMAD2/3 antibody (1:50 sc-
11769, Santa Cruz Biotechnology, Santa Cruz, CA) overnight.
The sections were then washed and incubated with a donkey
anti-rabbit Alexa 488 (1:1,000, Life Technologies, Carlsbad,
CA) and a donkey anti-goat Alexa 568 (1:1,000, Life
Technologies) for 45 min at room temperature. The negative
control was performed omitting the primary antibodies and
incubating tissues only with secondary antibodies for 45 min
at room temperature. Tissues were then counterstained with
DAPI and slides were mounted with Dako-Fluorescent
mounting Media (Dako, Carpinteria, CA). Slides were
observed using a Leica SP5 confocal microscope with a
63× N.A. 1.4 PL APO objective.
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Mucosal cell extraction. Fresh duodenal biopsies were
collected in calcium- and magnesium-free Hanks’ balanced
salt solution (HBSS, Euroclone, Italy) and rapidly processed.
Biopsy specimens were initially incubated in a HBSS solution
containing dithiothreitol (DTT, 0.145 mg/ml, Sigma-Aldrich,
St. Louis, MO) for 15 min to remove mucus and adherent
bacteria. After extensive washing in HBSS, biopsies were
incubated for 50 min with a HBSS solution containing
0.37 mg/ml EDTA (Sigma-Aldrich) at 37 °C. At the end,
supernatant was collected for intraepithelial lymphocytes
(IELs) analysis. After extensive washing in HBSS, biopsies
were then digested in RPMI 1640 medium (Euroclone, Italy),
containing 400 U/ml collagenase D (Roche, Milan, Italy)
in a 5% CO2 incubator at 37 °C for 1 h. After incubation,
LP mononuclear cells (LPMCs) released from the tissue
samples were passed through a 70 μm cell strainer and
washed with complete 10% RPMI 1640 medium.
Flow cytometry. Eight-color flow cytometer analysis was
performed using a FACS Canto II cytometer (Becton
Dickinson, BD Biosciences, San Jose, CA) after staining
with fluorochrome-conjugated antibodies. Unless indicated all
antibodies were from eBioscence (San Diego, CA). For
surface marker expression anti-CD4 (RPA-T4), anti-CD8
(SK1), anti-CD25 (BC96), anti-IL-7R (eBioRDR5) were used.
For Foxp3 intranuclear staining, Foxp3 staining Buffer set
(eBioscence) and anti-Foxp3 (PCH101) was used following
manufacturer’s recommendations. For intracellular cytokine
detection, LPMCs and IELs were incubated for 5 h in the
presence or absence of PMA, ionomycin and brefeldin A
(Sigma-Aldrich). Subsequently, cells were surface-labeled with
conjugated antibodies. After fixation with 2% paraformalde-
hyde (Merck), cells were permeabilized with PBS-0.5% saponin
(Sigma) and stained with anti-IL-10 (JES3-9D7), anti-IL-17
(eBio64DEC17), anti-IL-22 (22URTI), anti-IFN-γ (4S.B3) and
anti-GM-CSF (BVD2-21C11) antibodies. FACS data were
analyzed with FlowJo software (TreeStar, Ashland, OR).
Phenotypic analysis of antigen-presenting cells (APC) cells in
LP was performed by surface staining with anti-CD3 (SK7,
BioLegend, San Diego, CA), CD16 (CD16, BD), -CD19 (HIB19,
BD), -CD56 (B159, BD) as lineage markers, anti-CD11c (B-ly6,
BD), anti-CD14 (61D3, BD), anti- HLA-DR (L243, BioLegend),
anti-CD103 (Ber-ACT8, BD) and anti-CX3CR1 (2A9-1, Miltenyi
Biotec, Auburn, CA). DC were gated as lineage−HLA-
DR+CD11c+ and macrophages as HLA-DR+CD14+.
T-cell stimulation. In vitro T cell receptor (TCR) stimulation
of IELs and LPMCs isolated from the AIE patient or healthy
controls was performed with plate-bound anti-CD3 and
anti-CD28 Abs (2 μg/ml, BD) in the absence or presence of
IL-17-promoting cytokines (TGF-β1, IL-1β, IL-6, and IL-23).
All recombinant cytokines (R&D Systems, Minneapolis, MN)
were added at 10 ng/ml, with the exception of TGF-β1 that
were used at 1 ng/ml. After 4d on coated plates, cells were
cultured for another 48 h in uncoated plates and then
analyzed for intracellular cytokine production as previously
described. To assess LAP (Latency-Associated Protein) and
GARP (glycoprotein A repetitions predominant) expression,
peripheral blood mononuclear cells were purified from the
AIE patient and from 6 different healthy subjects using
standard Ficoll-Paque gradient centrifugation. Different T-cell
subsets were sorted on a FACSAriaII (BD) according to the
expression of specific surface markers: Treg cells were sorted
as CD4+IL7RlowCD25+ cells, whereas helper T cells were
sorted as CD4+IL7RhighCD25− cells. After 3 days of TCR-
dependent stimulation in plate-bound anti-CD3 and
anti-CD28 Abs (2 μg/ml, BD Biosciences), Treg and helper
T cells were stained with anti-GARP PeCy7 (G14D9,
eBioscence) and anti-LAP (FNLAP, eBioscence) antibodies.
Flow cytometry was performed using a FACS CANTO system
(BD Biosciences) and FACS data were analyzed with FlowJo
software (TreeStar).
Suppression assay. LPMCs and IELs from the AIE patient
and from four untreated active CD as control were purified as
previously described. CD4+ and CD8+ IELs were activated
with anti-CD3/anti-CD28 Abs and IL-17 promoting cytokines
for 4d in the presence or absence of autologous Treg
cells (ratio 10:1) sorting isolated as CD4+IL7RlowCD25+ cells
from LPMCs by a FACSAriaII (BD Biosciences). After 4d
on coated plates, cells were cultured for another 48 h in
uncoated plates and then analyzed for intracellular cytokine
production as previously described.
Statistics. Statistical analysis was performed with Prism 5
software (GraphPad Software, La Jolla, CA). Student's t-tests
for paired samples or one way anova (Tukey’s multiple
comparison test) were used to evaluate differences between
groups of variables. Statistical significance was set at
*Po0.05, **Po0.005, and ***Po0.0005.
RESULTS
Severe villous atrophy and massive duodenal T-cell
infiltration in a case of severe AIE. Histological examina-
tion of the duodenum in AIE documented a severe villous
atrophy and a massive infiltration of both the LP and the
intraepithelial layer by mononuclear cells, including lympho-
cytes and eosinophilic granulocytes (Figure 1a). Steroid
(T= 1) and azathioprine treatment (T=2) determined a
strong reduction of the inflammatory cell infiltrate, which
was evident both in the LP and in the epithelial layer. Of note,
a partial regrowth of intestinal villi was observed after the
combined treatments at 6 months (T=2). Immunohistochem-
istry analysis further demonstrated that lymphocytes that
infiltrated the LP and the epithelial layer contained both CD4+
and CD8+ T cells. TCR clonotyping on whole duodenal biopsies
documented a polyclonal γ/δ T-cell repertoire (Figure 1b),
thereby excluding the diagnosis of intestinal T-cell lymphoma.
Reduced expression of Foxp3, but not of IL-10, by
duodenal CD4+ T cells in AIE. In order to characterize
infiltrating T cells in AIE more in detail, we extracted
mononuclear cells from the LP of duodenal biopsies before
and after treatments, and compared them to non-inflamed
duodenal control biopsies. Since non-IPEX AIE is character-
ized by reduced numbers of Foxp3-expressing Tregs in the
CD4+ T-cell compartment, we first analyzed CD4+ regulatory
and helper T-cell subsets. (Figure 2a). Of note, Foxp3+Tregs
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Figure 1 Massive duodenal lymphocytic infiltration in autoimmune enteropathy (AIE). Data from duodenal biopsies of the AIE patient at baseline (PRE), 8 weeks after
initiation of steroid therapy (T= 1) and at 6 months, under azathioprine therapy (T= 2), are reported, together with those obtained from a cohort of subjects without signs of
duodenal inflammation (CTR). (a) Histological sections (original magnification × 10) obtained from duodenal biopsies of the AIE patient and from a representative control.
Hematoxylin and Eosin staining (H&E), and immunohistochemistry for CD3, CD4, and CD8 are reported. (b) TCR spectratyping of γ/δT cells revealed a polyclonal γ/δ T-cell pool
and ruled out lymphoma.
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have a CD4+CD25hiIL-7Rlo phenotype in healthy individuals,
while a second subset of Tregs in humans is also CD4+
IL-7Rlo, but lacks CD25 and Foxp3 expression and produces
large amounts of the anti-inflammatory cytokine IL-10.13 Data
from mouse models indicates that Foxp3−IL-10+ “type 1
regulatory T cells (Tr1)” are also highly relevant for intestinal
immune homeostasis.14 Both in AIE and controls the large
majority of duodenal LP CD4+T cells displayed an
IL-7RhiCD25− /lo helper phenotype (Figure 2a left panel).
Only small fractions of regulatory CD25hiIL-7Rlo and
CD25−IL-7R− subsets could be detected, and there were
no major differences in the frequencies of these regulatory
T-cell subsets between AIE and control subjects (Figure 2a
right panel). We next analyzed LP CD4+ T cells for Foxp3 and
IL-10 expression that are characteristic for Tregs and
Tr1 cells, respectively. Consistent with previously described
non-IPEX AIE cases,8 Foxp3 expression in intestinal
CD4+CD25hiIL-7Rlo T cells was markedly reduced (23.3%
vs. 64.1±1.6%, respectively, in AIE and controls), and only
slightly increased upon treatments (Figure 2b). No mutations
were identified by sequencing the Foxp3 gene (data not
shown), ruling out that the patient was affected by IPEX.
Conversely, IL-10 production was relatively high in active AIE
and decreased upon treatments (Figure 2c). Thus, AIE is
associated with defective expression of Foxp3, while IL-10
production by CD4+ T cells is not reduced.
Uncontrolled IL-17 production by IELs in active AIE is
reverted by immune-modulatory therapies. We next
analyzed the frequencies and cytokine profiles of CD4+ and
CD8+ T cells in the duodenal LP and in the intraepithelial
compartments. We observed a selective and dramatic
increase of CD8+ T cells but not of CD4+ T cells in the LP
(Figure 3a). Of note, the intraepithelial compartment was
largely unchanged displaying no major alterations in the
frequencies of CD4+ and CD8+ T cells (Figure 3b).
We next evaluated the effector cytokine profile of CD4+ and
CD8+ T cells extracted from the LP (Figure 3c) and from the
intraepithelial compartment (Figure 3d). We focused our
attention on the expression of IFN-γ and IL-17, since T helper
cells that co-produce these cytokines are associated with
intestinal inflammation.15–17 We also assessed the production
of IL-22 and GM-CSF, two additional key cytokines regulating
intestinal homeostasis.18,19 We observed increased levels of
IL-17 production by LP CD4+lymphocytes in active AIE that
was largely reverted upon therapy-induced resolution of
inflammation (Figure 3e, upper panel). Conversely, no major
differences were found between AIE and controls in the
proportion of CD4+T cells producing IFN-γ (Figure 3e),
GM-CSF or IL-22 (Supplementary Figure 1 online). LP CD8+
T cells expressed very high levels of IFN-γ in all cases, but
IL-17-producing and IL-17/IFN-γ co-producing CD8+ T cells
were rare (Figure 3e lower panel). Noteworthy, a dramatic
increase of IL-17-producing lymphocytes was found in
the intraepithelial compartment. (Figure 3f). As shown,
IL-17-producing CD4+ T cells were more strongly increased
in the intraepithelial compartment as compared to the LP, and
IL-17/IFN-γ co-producing cells were also more frequent
(Figure 3f). Moreover, in active AIE also CD8+ IELs produced
very high levels of IL-17, the large majority of these
IL-17+CD8+ IELs also co-producing IFN-γ (Figure 3f, lower
panel). In marked contrast, in healthy controls IL-17/IFN-γ co-
producing CD8+ IELs were nearly undetectable (Figure 3f).
Furthermore, steroid and azathioprine treatments strongly
reduced IL-17 production in particular in the intraepithelial
compartment. To exclude that enhanced IL-17 expression was
merely resulting from the ongoing mucosal inflammation, ileal
biopsies from a group of patients with active Crohn’s disease
were analyzed. As shown in Supplementary Figure 2 online,
enhanced percentages of IL-17-producing CD4+ and CD8+
T cells were found both in the LP and in the intraepithelium
compartment of active Crohn’s disease patients as compared
to uninflamed controls as expected. However, while the
fraction of IL-17-producing T cells in Crohn’s disease and
AIE were similar in the LP, IL-17+ IELs were much more
frequent in AIE, in particular in the CD8 compartment.
Figure 2 Reduced Foxp3 expression, but enhanced interleukin (IL)-10 production in LP CD4+ T cells in AIE. (a) Left panel: surface expression of the IL-7R and CD25 on
gated lamina propria (LP) CD4+ T cells from the AIE patient with active disease (PRE) or after cortisone (T= 1) and azathioprine treatment (T= 2) and a control patient as
representative control. Right panel: frequencies of IL-7RhighCD25− helper T cells, IL-7RloCD25+ Tregs and IL-7R−CD25+ Tr1-like cells in autoimmune enteropathy (AIE) and six
control donors. (b) Histogram showing intracellular reduced expression levels of FoxP3 on gated LP CD4+CD25+ Treg cells (red line) from the AIE patient and control, in
comparison with expression in CD4+IL-7R+ helper T cells (blue line). Frequencies of IL-7RloCD25+ Tregs in AIE and six control donors are reported on the right. (c) IL-10
production by LP CD4+T cells after brief polyclonal stimulation in AIE and six control donors.
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These data suggest that AIE is characterized by a selective
increase of IL-17-producing LP CD4+ T cells, and by the
massive appearance of unconventional IL-17 and IFN-γ
co-producing CD4+ and CD8+ IELs. In particular IL-17-
producing CD8+ IELs are largely absent in the healthy
duodenum and rare in the ileum of Crohn’s disease patients,
and disappear upon therapy-induced resolution of inflammation.
TGF-β and pro-inflammatory cytokines jointly induce
IL-17 production in CD8+ IELs. In order to understand if
IL-17 and IFN-γ co-producing IELs could be generated locally
upon inflammation, we activated IELs and LPMCs extracted
from control biopsies with anti-CD3 and anti-CD28 antibodies
in the absence and presence of an optimal combination of
IL-17-promoting cytokines,17,20–23 namely high amounts of
IL-1β, IL-6 and IL-23 and low amounts of TGF-β1 (Figure 4).
CD4+ and CD8+ T cells from the intraepithelial compartment
rapidly upregulated IL-17 production in response to TCR
stimulation and Th17-promoting cytokines (Figure 4a). Inter-
estingly, LP T cells had largely different requirements,
since TCR stimulation alone was sufficient for the upregula-
tion of IL-17 in LP CD4+ T cells, while IL-17 induction in LP
CD8+ T cells was enhanced by cytokines, but inefficient
when compared to other intestinal T-cell subsets (Figure
4b left panel). Of note, CD8+ IELs acquired very high
IL-17-producing capacities in response to TCR stimulation
and Th17-promoting cytokines, similar to the abundant levels
observed in active AIE (Figure 4b right panel). IFN-γ
production was highly expressed under all conditions, and
consequently the majority of both CD4+ and CD8+ T cells that
had upregulated IL-17 expression co-produced IFN-γ.
The efficient cytokine-dependent induction of IL-17 in IELs
prompted us to define the contribution of individual cytokines
to this unexpected cellular plasticity. We therefore measured
IFN-γ and IL-17 production in response to TCR stimulation and
Th17-promoting cytokines in CD4+ and CD8+ IELs and
analyzed their modulation in the selective absence of either
IL-2317 or TGF-β123 (Figure 4c). The absence of TGF-β1
induced a strong and significant reduction of IL-17 production
in CD8+ IELs, but had only a weak and not significant effect on
IL-17 production by CD4+ IELs (Figure 4c, left panel).
Furthermore, the effect of TGF-β1 was specific for IL-17,
since IFN-γ production did not change significantly. Conver-
sely, the absence of IL-23 had only a rather weak inhibitory
effect on IL-17 induction in both CD4+ and CD8+ IELs
(Figure 4c, right panel).
We conclude that TCR-activated IELs efficiently acquire
IL-17-producing capacities without losing IFN-γ production in
the presence of Th17-promoting cytokines. Intriguingly, TGF-β
strongly enhanced the generation of IL-17 and IFN-γ co-
producing CD8+ IELs, but had no relevant effect on CD4+ IELs.
Foxp3lowTregs upregulate TGF-β and enhance IL-17
induction in CD8+ IELs. Foxp3lowCD4+CD25+ Tregs from
peripheral blood of AIE patients have reduced capacities to
suppress the proliferation of circulating CD4+CD25− helper
T cells,7 but efficiently suppress IL-2 and IFN-γ production.8
On the contrary, the capacity of LP Tregs to suppress
Figure 3 Autoimmune enteropathy (AIE) is associated with high interleukin (IL)-17 production by IELs. (a-b) Quantitative flow cytometric analysis of the relative percentages
of CD4+ and CD8+ T cells among lymphocytes that were extracted from the duodenal lamina propria (LP mononuclear cells (LPMCs), (a) and from the intraepithelial compartment
(IELs, (b) of the AIE patient before (PRE) and after treatments (POST) with steroids (8 weeks, T= 1) or azathioprine (6 months, T= 2) and from a cohort of six subjects without
signs of duodenal inflammation (CTR). (c,d) Intracellular expression of IL-17 and interferon-γ (IFN-γ) in gated LP CD4+, CD8+ T cells as well as in CD4+ IELs and CD8+ IELs from
the analyzed AIE patient at different time points (active disease: PRE; after 6 months: POST) and in control donors (CTR). Dot plots show intracellular IL-17 and IFN-γ production
following brief in vitro polyclonal stimulation. (e,f) Percentages of CD4+ and CD8+ T cells that produce either IL-17 (left), IFN-γ (right) or that co-produce IFN-γ and IL-17 (middle)
in the AIE patient at different time points as compared to the six controls in the LP (e) and intraepithelial compartments (f).
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intestinal T-cell responses in AIE has not been addressed yet,
presumably due to the technical difficulties to isolate sufficient
numbers of these rare Tregs (Figure 2a) from intestinal
biopsies. In order to evaluate whether the increased
expression of IL-17 in AIE by duodenal IELs was directly
linked to a functional defect of Foxp3lowTregs, we set up a
suppression assay where IL-17 production was induced in
TCR-activated IELs with an optimal cytokine cocktail in the
absence or presence of autologous Tregs isolated ex vivo
from the LP. Duodenal Tregs from patients with CD, a clinical
condition in which suppressive Tregs accumulate in the
duodenum,24 were used as controls. Notably, ex vivo IL-17
and/or IFN-γ production by duodenal T-cell subsets were
similar in CD patients and uninflamed control patients
(Figure 5a), and in particular IL-17 production by CD8+ IELs
were in both groups hardly detectable. Duodenal Tregs from
CD patients strongly inhibited IL-17 upregulation of auto-
logous CD8+ IELs, but had interestingly a weaker inhibitory
effect on CD4+ IELs (Figure 5b). Moreover, IFN-γ production
by CD8+ IELs was largely unaffected by the presence of
Tregs, showing that mucosal Tregs control selectively the
production of IL-17 by CD8+ IELs. In marked contrast,
although duodenal Foxp3lowTregs in AIE also slightly reduced
IL-17 expression in CD4+ IELs, they failed to inhibit IL-17
production by CD8+ IELs and even increased IL-17 secretion
(Figure 5b).
CD25+ Tregs are unable to produce pro-inflammatory
cytokines, but unlike helper T cells they upregulate
membrane-bound TGF-β in its latent form (LAP, Latency
Associated Protein), which is presented by the Treg-specific
surface receptor GARP (glycoprotein A repetitions predomi-
nant).25 Notably, TGF-β signaling in mouse effector T cells is
required for the inhibition of experimental colitis by Foxp3+-
Tregs.26 We wondered if the dysfunctional Foxp3lowTregs in
AIE could enhance IL-17 production of CD8+IELs via TGF-β,
and to this end we compared the capacity of CD4+CD25+
IL-7Rlow Tregs to upregulate GARP and LAP surface expres-
sion following TCR activation (Figure 5c). Foxp3lowTregs
upregulated GARP and LAP similar to Tregs from healthy
controls, indicating that the induction of membrane-bound
TGF-β production was not inhibited in Foxp3lowTregs in AIE.
Finally, to address whether CD8+ IELs also received signals
from TGF-β in AIE in vivo, we stained duodenal AIE sections
for CD8 and phosphorylated Smad2/3, (p-SMAD2/3), since
Figure 4 Pro-inflammatory cytokines and transforming growth factor-β1 (TGF-β1) induce high levels of IL-17 in CD8+ IELs. Intracellular expression of interleukin (IL)-17,
interferon-γ (IFN-γ) as well as co-expression interferon-γ (IFN-γ)/IL-17, in gated CD4+ and CD8+ (LP mononuclear cells (LPMCs) and intraepithelials (IELs)) extracted from a
cohort of six subjects without signs of duodenal inflammation. T cells were activated with anti-CD3 and anti-CD28 in the absence (anti-CD3/28) or presence of IL-17 promoting
cytokines (TGF-β1, IL-1β, IL-6 and IL-23; Th17 cytokines) and compared to ex vivo expression of IFN-γ and/or IL-17. (a) Representative stainings of stimulated CD4+ and CD8+
IELs. (b) Shown are the mean percentages and the s.e.m. * and ** at the top of the column indicates statistical significance as compared to ex vivo cytokine production (mean of
ex vivo cytokine production is indicated by the black dotted line). (c) Mean variation of intracellular expression of IL-17 and/or IFN-γ induced with anti-CD3/CD28 antibodies and
IL-17 promoting cytokines in CD4+ and CD8+ IELs in the selective absence of either TGF-β1 (w/o TGF-β) or IL-23 (w/o IL-23). Shown are the mean variations (fold change) and s.
e.m. * and ** at the top of the column indicates statistical significance as compared with TCR stimulation in the presence of T helper 17 (Th17) cytokines indicated by the black
dotted line.
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the latter are phosphorylated and thus activated upon TGF-β
receptor (TGF-β R) engagement. As shown in Figure 5d, we
observed a higher number of CD8+ cells (green cells) in active
AIE (PRE) in situ compared to healthy controls that decreased
upon therapy as expected. Moreover, p-Smad2/3 positive cells
(red) were present both in the steady state and in AIE before
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and after treatment. Moreover, some CD8+ lymphocytes were
positive for p-Smad2/3 in all cases, suggesting that they were
exposed to and activated by TGF-β in vivo both in the healthy
gut and in AIE.
In conclusion, while normal duodenal Tregs suppress IL-17
production by IELs, Foxp3lowTregs in AIE, not only failed to
suppress, but even enhanced IL-17 production in CD8+ IELs.
This paradoxic finding could be explained by the fact
that Foxp3lowTregs efficiently upregulated membrane-bound
TGF-β, which in turn could enhance IL-17 production by CD8+
IELs. Consistent with this scenario, TGF-β signaling in CD8+
IELs could be detected in situ in active AIE, demonstrating that
bioactive TGF-βwas present under this inflammatory condition.
Enhanced CD103 expression on DC and macrophages in
active AIE. Intestinal T-cell polarization towards effector or
regulatory subclasses is largely dependent on cytokine
production by mucosal antigen-presenting cells (APCs).27
To investigate whether alterations in mucosal APCs might be
associated with the enhanced IL-17 production of T-cell
subsets in AIE, we analyzed APC extracted from duodenal
AIE LP at baseline and following drug-induced remission,
and results were compared with healthy controls. Since
intestinal APC subsets are distinguished by CD103 and
CX3CR1 expression, we analyzed the expression of these
surface markers among both DC and macrophages, identi-
fied as lin−HLA-DR+CD11c+ and HLA-DR+CD14+ cells,
respectively.28 In comparison with healthy controls, a higher
proportion of DCs and macrophages expressed CD103 in
active AIE (Supplementary Figure 3 online), while a reduced
proportion of CX3CR1+ cells were found. Steroid treatment
reduced the expression of CD103, and increased the
expression of CX3CR1 on both mucosal DC and on
macrophages. Thus, the dysregulated T-cell homeostasis in
AIE is associated with an increased frequency of CD103+DC
and macrophages that is partially reverted by steroid therapy.
DISCUSSION
AIE is a fascinating disease from an immunological perspec-
tive, as insights into its pathogenesis may lead to valuable
information regarding mechanisms of tolerance and in vivo
regulation of immune responses in the human gut. Specifi-
cally, the recognition that most AIE cases are secondary to
reduced numbers and functions of Foxp3+ Tregs7 makes this
rare disease a model to study a partial defect of Tregs in the
modulation of intestinal immune homeostasis. However, most
studies on AIE pathogenesis focused on the reduced numbers
and functions of Tregs in peripheral blood rather than
analyzing functional or phenotypic changes in regulatory
and effector lymphocytes in the intestine. Nevertheless, such
information would be of relevance in designing novel anti-
inflammatory drugs and therapeutic approaches for this rare
condition.
The here analyzed AIE patient had severe duodenal
inflammation, an elevated titer of anti-enterocyte antibodies
and reduced Foxp3 expression in CD25+ Tregs; moreover γ/δ
lymphoma, IPEX as well as CD were ruled out, indicating that
she was actually affected by AIE.6,8 Intestinal homeostasis
requires not only Foxp3+Tregs but also IL-10,29 that can
be provided by both Foxp3+ and Foxp3− CD4+ Tregs in
mice.14,30–32 Consistently, defects in the IL-10/IL-10R pathway
induces severe early-onset colitis in humans.33 We detected
relatively high IL-10 production by CD4+ T cells in active AIE
(PRE) that diminished upon treatment-induced remission,
indicating that defective Foxp3 expression in Tregs but not
impaired IL-10 production is the underlying defect in AIE.
Consistent with previous reports,34 we found that the small
intestinal mucosa was massively infiltrated with T cells during
active AIE, with a preponderance of CD8+ over CD4+ T cells in
the LP. In addition, we observed a very selective upregulation
of IL-17 in LP CD4+T cells. These alterations were largely
reverted upon treatment-induced mucosal healing. IL-17 is
important for epithelial barrier function and has anti-microbial
as well as pro-inflammatory activities, and the upregulation of
IL-17might be anunsuccessful attempt by the intestinal immune
system to re-establish gut homeostasis in AIE. Indeed, while
anti-IFN-γ antibodies had a beneficial effect in IBD patients, anti-
IL-17A was unexpectedly detrimental.35 Nevertheless, mucosal
Th17 cells and in particular those co-producing IL-17 and IFN-γ
or GM-CSF could also drive chronic intestinal inflammation, and
might thus also play a pathogenic role.15,19,36
A secondmajor change in active AIE that was reverted upon
mucosal healing was the abundant IL-17 production by IELs,
in particular IL-17 and IFN-γ-co-producing CD8+IELs. Impor-
tantly, IL-17-producing CD8+ IELs were rare in other inflam-
matory diseases of the small intestine, such as CD and ileal
Crohn’s disease. CD8+IELs have been implicated in multiple
pathological processes of the small intestine, including the
progression of inflammatory bowel diseases,37 as well as in
the pathogenesis of CD by directly targeting intestinal
epithelial cells and causing villous atrophy.38,39 In addition,
IFN-γ/IL-17 co-producing CD8+ T cells have been described in
other immunological disorders of the intestine, including active
Figure 5 Regulation of intraepithelial (IEL) interleukin (IL)-17 production and upregulation of latent TGF-β by CD25+Tregs. (a) Intracellular expression of IL-17 and/or IFN-γ in
CD4+ and CD8+ IELs from the analyzed autoimmune enteropathy (AIE) patient (dashed line), in celiac disease (CD, black bars) and control donors (CTR, white bars). IFN-γ and/
or IL-17 production was measured by intracellular staining following brief polyclonal re-stimulation. Shown are the mean percentages and s.e.m. (b) IELs and autologous
duodenal LP CD25+IL-7Rlo Tregs from the AIE patient and from 4 celiac disease (CD) patients were co-cultured at a 10:1 ratio and stimulated with anti-CD3 and -CD28 antibodies
and Th17-promoting cytokines for 6 days. IFN-γ and IL-17 production was measured by intracellular staining following brief polyclonal re-stimulation. Shown are the mean
percentages and the statistical significances. (c) Peripheral blood CD25+IL-7Rlo Tregs and CD25−IL-7Rhigh helper T cells from the AIE patient or from healthy donors were
stimulated with anti-CD3 and -CD28 antibodies for 3 days and surface LAP and GARP expression analyzed by flow cytometry. Histogram showing surface expression levels of
GARP and LAP on LP CD4+CD25+ Treg cells from the AIE patient (blue line) and control (red line), in comparison with expression in CD4+IL-7R+ helper T cells (black dotted line).
Mean of frequency (MFI) of GARP and LAP expression on IL-7RloCD25+ regulatory T cells (Tregs) in AIE (black dots) and control donors (white bars) are reported. (d) Duodenal
biopsies from the AIE patient before (PRE) and after treatments with steroids (8 weeks, T= 1) or azathioprine (6 months, T= 2) and from a representative control were immune-
stained for CD8 (green), p-SMAD2/3 (red), and nuclear stain (DAPI). Arrows indicates cells co-expressing CD8 and p-SMAD2/3. Scale bar: 50 um, original magnification 63x.
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CD40 and microscopic colitis.41 Interestingly, recent evidence
in mice suggests that IELs may be under the direct control of
intestinal Tregs, as an experimental reduction in numbers and
functionality of Tregs leads to a severe form of intestinal
inflammation characterized by infiltration of the intraepithelial
compartment by IL-17-secreting CD8+ T cells.42 Consistently,
we found that the induction of IL-17-producing CD8+IELs in
humans was inhibited by Tregs in control patients, but not in
AIE. IL-17 and IFN-γ co-producing T cells can be generated
from IL-17-producing CD4+ T cells with cytokines that induce
IFN-γ, such as IL-1β and IL-23 or IL-12.20,43 In contrast, we
showed here that IFN-γ-producing CD8+IELs could acquire
IL-17 production without losing IFN-γ production in response
to a cocktail of IL-17-promoting cytokines, i.e., IL-1β, IL-6,
IL-23 and TGF-β1. IELs are thus not terminally differentiated
cells but are highly plastic,43 and could change their cytokine
profile in response to locally uncontrolled cytokine production.
Pro-inflammatory cytokines in the LP are probably derived
from myeloid cells, and interestingly we observed increased
frequencies of CD103+ myeloid cells in active AIE. Indeed,
intestinal CD103+DC produce pro-inflammatory cytokines and
induce Th17 differentiation in mice.44
An important and unexpected finding of this study was that
IL-17 production by IELs and LP T cells had largely different
requirements.45 Thus, while LP CD4+ T cells rapidly upregu-
lated IL-17 upon TCR stimulation in the absence of exogenous
cytokines, LP CD8+ T cells poorly upregulated IL-17 production
even under optimal Th17 conditions, consistent with their low
IL-17 production in active AIE. Intriguingly, the anti-
inflammatory cytokine TGF-β, which strongly inhibits the
induction of IFN-γ production in naïve CD4+ T cells19,44 and
restrains colitis,26 enhanced IL-17 production in CD8+IELs, but
had no inhibitory effect on IFN-γ. This enhancing
effect of TGF-β was specific for CD8+ IELs, because TGF-β
had no enhancing effect on CD4+IELs. Thus, pro-inflammatory
cytokineswere sufficient to induce IL-17 in TCR-activatedCD4+
IELs, possibly because they contain pre-committed Th17 cell
precursors46,47 which do not require TGF-β to upregulate
IL-17.46,48 Finally, our data suggests that a relevant source of
intestinal TGF-β, which promotes IL-17 induction in CD8+ IELs
in AIE, might be the defective Foxp3lowTregs themselves.
Indeed, latent TGF-βwas efficiently and selectively upregulated
on Foxp3lowTregs in AIE, and the latter further enhanced IL-17
production selectively by CD8+IELs. Thus, the defective
Foxp3lowTregs might enhance IL-17 production by CD8+IELs
via TGF-β Moreover, some duodenal CD8+T cells contained
phosphorylated Smad2/3, demonstrating that they received
signals from the TGF-βR also under inflammatory conditions
in vivo and suggesting that bioactive TGF-β was available.
Indeed, it was previously shown in mice that the presence of
apoptotic cells and pathogen-associated molecular patterns in
the inflamed intestine is a physiological situation that leads to
the induction of both TGF-β and pro-inflammatory cytokines.49
Overall these findings indicate that TGF-β plays an important
role not only in the steady state, but also under inflammatory
conditions.
In conclusion, our data shows that in AIE the quantitative
deficit of Foxp3 expression in intestinal CD4+CD25+Tregs is
associated with a selectively dysregulated IL-17 production in
particular by CD8+ lymphocytes in the epithelium, which is
reverted upon successful pharmacological treatment. The
enhanced IL-17 production by both CD4+ and CD8+IELs in
AIE suggests that human Foxp3+Tregs have a non-redundant
role to control IL-17 production by IELs. Moreover, TGF-β,
possibly derived from defective Tregs in AIE, could be
selectively important for IL-17 production by CD8+IELs. This
data broadens our understanding on the role of Foxp3+Tregs
and TGF-β in intestinal immune homeostasis, and raises the
question if mongersen, an efficient treatment of Crohn’s
disease50 that enhances TGF-β responsiveness, is also an
appropriate treatment for AIE.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
• Autoimmune enteropathy (AIE) is caused by a quantitative
deficit in Foxp3 expression and suppressive functions
of CD25+ regulatory T cells, and results in massive
lymphocytic infiltration of the small intestine.
• Existing knowledge regarding AIE pathophysiology mostly
derives from studies conducted on peripheral blood cells or
histological sections, while little is known regarding
phenotypic and functional characteristics of inflammatory
cells that infiltrate the intestinal mucosa.
WHAT IS NEW HERE
• AIE is associated with a selective dysregulation of
interleukin (IL-17) production in different intestinal T-cell
compartments, in particular in intraepithelials (IELs).
• TCR-activated IL-17 production has different requirements
for pro-inflammatory cytokines and transforming growth
factor-β (TGF-β) in CD4+ and CD8+ T cells in the LP and the
intraepithelial compartment.
• Bioactive TGF-β is present in the intestinal mucosa of
active AIE.
• Foxp3lowTregs with reduced suppressive functions in AIE
maintain the ability to produce TGF-β and enhance IL-17
production by CD8+ IELs.
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